Tumor necrosis factor-alpha: a possible priming agent for the polymorphonuclear leukocyte-reduced nicotinamide-adenine dinucleotide phosphate oxidase in hypertension.
In the Sabra rat, oxidative stress (OS) and inflammation precede the development of hypertension. Inhibition of the phagocytic NADPH oxidase attenuates the rise in blood pressure. The present study was set to identify possible priming agents for this enzyme and to test the hypothesis that the phagocytic NADPH oxidase contributes to OS and inflammation. Sabra salt-sensitive and Sabra salt-resistant rats were salt loaded or provided regular chow for 60 days with or without apocynin to inhibit NADPH oxidase. Levels of interleukin 6, tumor necrosis factor-alpha, and interferon-gamma served as indices of inflammation. Extracellular and intracellular levels of the polymorphonuclear leukocyte tumor necrosis factor-alpha receptors (p55 and p75) were assessed by flow cytometry in young and adult rats. NADPH oxidase activity and expression of p47phox were measured in polymorphonuclear leukocytes and aortic rings. Malondialdehyde and carbonylated fibrinogen served as indices of OS. Inflammatory and OS indices excluding interferon-gamma were higher in the hypertensive state and reduced by apocynin. Levels of malondialdehyde and tumor necrosis factor-alpha were elevated already in the prehypertensive state. No differences were found in the levels of p75. The extracellular expression of p55 was higher in adult Sabra salt-resistant compared with Sabra salt-sensitive rats (7.46+/-2.2% versus 2.1+/-0.5%; P<0.05), whereas levels of the intracellular p55 were higher in adult Sabra salt-sensitive rats (3.2+/-2% versus 1.1+/-0.5%; P<0.05). In young normotensive rats, the extracellular levels of p55 were higher in Sabra salt-sensitive compared with Sabra salt-resistant rats (10.6+/-5.2% versus 2.9+/-1.5%; P<0.01). Tumor necrosis factor-alpha plays a role in activation of the polymorphonuclear leukocyte NADPH oxidase, thereby contributing to systemic OS, inflammation, and the development of hypertension in this model.
Mazor
Rafi
R
Department of Nephrology and Hypertension, Eliachar Research Laboratory, Western Galilee Hospital, Naharyia, Israel. mazrafi@gmail.com
Itzhaki
Osnat
O
Sela
Shifra
S
Yagil
Yoram
Y
Cohen-Mazor
Meital
M
Yagil
Chana
C
Kristal
Batya
B
D000098:Acetophenones / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D001795:Blood Pressure Determination; D016207:Cytokines / Q000097:blood / Q000378:metabolism; D004195:Disease Models, Animal; D005786:Gene Expression Regulation; D006973:Hypertension / Q000201:enzymology*; D007150:Immunohistochemistry; D008315:Malondialdehyde / Q000378:metabolism; D019255:NADPH Oxidases / Q000187:drug effects / Q000378:metabolism*; D009504:Neutrophils / Q000201:enzymology* / Q000502:physiology; D018384:Oxidative Stress / Q000502:physiology; D011336:Probability; D011897:Random Allocation; D051381:Rats; D011918:Rats, Inbred SHR; D017673:Sodium Chloride, Dietary / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism*
D000098:Acetophenones; D016207:Cytokines; D017673:Sodium Chloride, Dietary; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; C056165:acetovanillone; D019255:NADPH Oxidases